Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398417 | 0.90 | MCHR1 (0.47) | MCHR1TSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6397474 | 0.90 | BTK (0.49) | TSHRNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6402241 | 0.89 | TSHR (0.44) | MCHR1TSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29087291 | 0.83 | PTGDR2 (0.48) | NPC1RAB9ASMN1; SMN2KDM1AMEN1 | |
| SCHEMBL6399007 | 0.83 | CCR1 (0.55) | TSHRNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6401881 | 0.83 | TSHR (0.47) | TSHRNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL748649 | 0.82 | MEN1 (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM1A | |
| SCHEMBL7982809 | 0.81 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2KDM1AMEN1 | |
| SCHEMBL1498503 | 0.81 | MAPT (0.53) | TSHRNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6397390 | 0.79 | NPC1 (0.46) | TSHRNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943267-B1 | compounds structurally resemble the substrates of the enzymes, but have nonhydrolyzable mono protonated thiophosphonate salts; chromatography or distillations not required | UTAH STATE UNIVERSITY (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050054683-A1 | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | HUTCHINSON DOUGLAS K (US) | 2005-03-10 | — | — | US | disclosed |
| US-20050049431-A1 | Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases | UTAH STATE UNIVERSITY | 2005-03-03 | — | — | US | disclosed |
| US-6358942-B1 | MICROBIOCIDES AND BACTERICIDES FOR TREATING GRAMPOSITIVE, BACTEROIDES, CLOSTRIDIUM, MYCOBACTERIUM, STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS | PHARMACIA & UPJOHN COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-6313307-B1 | DEBLOCKING, DEPROTECTING; CATALYTIC HYDROGENATION, ALKYLATION; PREPARING MICROBIOCIDES AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, MYCOBACTERIUM, AND CLOSTRIDIUM | PHARMACIA & UPJOHN COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-0856002-B1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | UPJOHN CO (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6166056-A | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | PHARMACIA (US) | 2000-12-26 | — | — | US | disclosed |
| US-6051716-A | ANTIMICROBIAL AGENTS | PHARMACIA & UPJOHN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6043266-A | MICROBIOCIDES TREATING GRAM-POSITIVE BACTERIA INFECTIONS AND PERSONS WITH AIDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| US-5968962-A | ANTIMICROBIAL AGENTS; EFFECTIVE AGAINST GRAMPOSITIVE BACTERIA | PHARMACIA & UPJOHN COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0856002-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997009328-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049431-A1 | Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases | PPME1, MTMR1, PTPRE | MCHR1 4562/4885TSHR 1052/4885NPC1 1931/4885 |
| US-20050054683-A1 | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | CBR1, NCOR1, RCOR1 | MCHR1 322/4885TSHR 630/4885NPC1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.